Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	ABN 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael SAMMELLS
Date of last notice	30/09/2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest		
(including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		
Date of change	22/12/2021	
No. of securities held prior to change	68,554 Direct – 68,554	
Class	FPO	
Number acquired	12,431	
Number disposed		
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,524.34	
No. of securities held after change	80,985 Direct- 80,985	

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of or of securities under dividend reinvestment plan, participa	
back	
Doub 2. Change of discrete 4s intercent	
Part 2 – Change of director's interest Note: In the case of a company, interests which come within lisclosed in this part.	paragraph (ii) of the definition of "notifiable interest of a director" should be
Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
•	
Date of change	
No. and class of securities to which	
Interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	
Part 3 – ⁺ Closed period	
Were the interests in the securities o above traded during a +closed period	

clearance was required?

this provided?

trade to proceed during this period?

If so, was prior written clearance provided to allow the

If prior written clearance was provided, on what date was

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	ABN 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christine BARTLETT
Date of last notice	30/09/2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	22/12/2021
No. of securities held prior to change	168,321 Direct - 168,321
Class	FPO
Number acquired	12,162
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,404.79
No. of securities held after change	180,483 Direct - 180,483

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of opti of securities under dividend reinvestment plan, participatio back	ons, issue	ourchased under NED's Share Plan
Part 2 — Change of director's interests Note: In the case of a company, interests which come within partisclosed in this part.		on of "notifiable interest of a director" should be
Detail of contract		
Nature of interest		
Name of registered holder (if issued securities)		
Date of change		
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed		
Interest acquired		
Interest disposed		
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation		
Interest after change		
Part 3 – ⁺ Closed period		
Were the interests in the securities or above traded during a +closed period w clearance was required?		
If so, was prior written clearance prov trade to proceed during this period?		
If prior written clearance was provided,	on what date wa	as

this provided?

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED	
ABN	ABN 15 088 417 403	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Gerald MANUEL
Date of last notice	30/09/2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	22/12/2021
No. of securities held prior to change	337,390 Direct – 337,390
Class	FPO
Number acquired	11,801
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,244.36
No. of securities held after change	349,191 Direct - 349,191

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of option of securities under dividend reinvestment plan, participation back	
Part 2 – Change of director's interests Note: In the case of a company, interests which come within padisclosed in this part.	in contracts ragraph (ii) of the definition of "notifiable interest of a director" should be
Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	
Part 3 – ⁺ Closed period	
Were the interests in the securities or above traded during a ⁺ closed period w clearance was required?	here prior written
If so, was prior written clearance prov trade to proceed during this period?	ided to allow the

this provided?

Appendix 3Y Page 2 01/01/2011

If prior written clearance was provided, on what date was

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED	
ABN	ABN 15 088 417 403	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Kathryn SPARGO
Date of last notice	30/09/2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Self-managed superannuation fund of Director Spargo Super Pty Ltd (atf Spargo Super Fund)
Date of change	22/12/2021
No. of securities held prior to change	280,317 Direct – 160,317 Indirect – 120,000
Class	FPO
Number acquired	14,349
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$6,376.70
No. of securities held after change	294,666 Direct – 174,666 Indirect – 120,000

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, is: of securities under dividend reinvestment plan, participation in b back	
Part 2 – Change of director's interests in orderests in the case of a company, interests which come within paragraphisclosed in this part.	
Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	
Part 3 – ⁺ Closed period	
Were the interests in the securities or con- above traded during a +closed period where clearance was required?	
If so, was prior written clearance provided trade to proceed during this period?	
If prior written clearance was provided, on	vhat date was

this provided?

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED	
ABN	ABN 15 088 417 403	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Raymond Mark GUNSTON
Date of last notice	30/09/2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	22/12/2021
No. of securities held prior to change	606,218 Direct – 606,218
Class	FPO
Number acquired	22,331
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$9,923.90
No. of securities held after change	628,549 Direct - 628,549

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of option of securities under dividend reinvestment plan, participation back	
Part 2 – Change of director's interests Note: In the case of a company, interests which come within particular disclosed in this part.	in contracts ragraph (ii) of the definition of "notifiable interest of a director" should be
Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	
Part 3 – ⁺ Closed period	
Were the interests in the securities or above traded during a +closed period w clearance was required?	
If so, was prior written clearance prov trade to proceed during this period?	
If prior written clearance was provided,	on what date was

this provided?

⁺ See chapter 19 for defined terms.